Stuttgart - Delayed Quote EUR

Fresenius Medical Care AG & Co. KGaA (FMEA.SG)

19.40

-0.20

(-1.02%)

At close: 3:26 PM GMT+2

Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week

Fresenius Medical Care AG ( ETR:FME ) shareholders should be happy to see the share price up 15% in the last month. But...

Simply Wall St. 19 hours ago

FMCQF

FMS
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

PR Newswire last month

FMCQF

FMS
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards. The glasses stream visual and acoustic recordings as users inte

PR Newswire last month

FMCQF

FMS
Health Care Roundup: Market Talk

Read about Green Thumb Industries, Bayer, Fresenius Medical Care and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal last month

FMCQF

FMS

CNVVF
Why Dialysis Stocks Are up Today

Investors’ focus on the potential for Ozempic to disrupt various industries was on full display Tuesday. The industry in question this time: dialysis. Shares of companies providing dialysis services to kidney-disease patients, including Fresenius, DaVita and Outset Medical, were all up—Fresenius by some 11%—after drugmaker Novo Nordisk released [new details from a study of Ozempic](https://www.

The Wall Street Journal last month

FMCQF

FMS

OM
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.

PR Newswire last month

FMCQF

FMS
Fresenius Swings to Net Loss After Fresenius Medical Care Deconsolidation

Fresenius reported an above-forecast 13% rise in underlying profit for the fourth quarter and forecast further growth in earnings and sales this year, and an improved cost-savings target for 2025.

The Wall Street Journal 2 months ago

FMCQF

FMS
Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "In 2023, we delivered on our commitments while we fundamentally transformed Fresenius Medical Care. Exceeding our upgraded financial outlook for the full year was the very successful finish to an extraordinary year. We implemented the new global operating model, progressed on our operational turnaround ambitions, changed our legal form and advanced on the Portfolio Optimization Program through key divestments. Thanks to the co

PR Newswire 2 months ago

FMCQF

FMS
Fresenius Medical Care Net Profit Rises on Cost Savings

Fresenius Medical Care reported above-forecast results for the fourth quarter as cost savings offset flat revenue, and guided for robust earnings and sales growth this year.

The Wall Street Journal 2 months ago

FMCQF

FMS
Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company's 5008X Hemodialysis System. Now the company wants to bring a new standard of care in dialysis therapy to people living with kidney diseases in the U.S.

PR Newswire 2 months ago

FMCQF

FMS
Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in German

PR Newswire 2 months ago

FMCQF

FMS
Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program. Refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of

PR Newswire 3 months ago

ICGUF

FMCQF

FMS
Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announces the successful completion of its change of legal form from a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a German stock corporation (Aktiengesellschaft, AG) as of November 30, 2023. With this important milestone, Fresenius Medical Care is opening a new chapter in the history of the Company with a simplified corporate governance structure tha

PR Newswire 4 months ago

FMCQF

FMS
Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, resolved a legal dispute with the U.S. government, for accounts receivable in legal dispute, and entered into a final and legally binding settlement agreement today, whereby the company will receive a payment from the U.S. government.

PR Newswire 5 months ago

FMCQF

FMS
Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "Our unwavering focus on executing against our strategic plan and the successful implementation of turnaround measures to date, continue to translate into improved operating performance. Notably in the third quarter, we continued to unlock sustainable savings with our FME25 program, further improved our labor productivity and continued to execute on our portfolio optimization plan. Given our improving performance for the first

PR Newswire 5 months ago

FMCQF

FMS
Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment. Cordola will start on January 1, 2024, as Chief Executive Officer of Care Delivery. He will be based in Waltham, Massachusetts.

PR Newswire 5 months ago

FMCQF

FMS
Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of over 60 company-affiliated research abstracts at the American Society of Nephrology's (ASN) Kidney Week 2023 taking place November 2-5 in Philadelphia.

PR Newswire 5 months ago

FMCQF

FMS
Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the phase-one completion of the company's first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company's long-term AI aspirations. Intended to advance patient care quality and outcomes by making kidney disease care more personalized and precise, the database provides a highly sophisticated view into the clinical care provi

PR Newswire 5 months ago

FMCQF

FMS
Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer and manager of multifamily communities, announced today the sale of a medical building in Winchester, Virginia. The property was owned by a group of DST investors who realized a 149.09% total return, or a 6.78% annualized return, from their 1031 exchange investment.*

PR Newswire 6 months ago

FMCQF

FMS
Capital Square Delivers 147.63% Total Return* to Investors in Medical Building DST

Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer of multifamily communities, announced today the sale of a medical building in Kinston, North Carolina. The property was owned by a group of DST investors who realized 147.63% total return, or a 7.15% annualized return, from their 1031 exchange investment.*

PR Newswire 6 months ago

FMCQF

FMS

Performance Overview

Return	FMEA.SG	DAX PERFORMANCE-INDEX
YTD	+3.19%	+7.98%
1-Year	-2.16%	+13.90%
3-Year	-36.02%	+18.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fresenius Medical Care AG & Co. KGaA (FMEA.SG)

Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Health Care Roundup: Market Talk

Why Dialysis Stocks Are up Today

Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Fresenius Swings to Net Loss After Fresenius Medical Care Deconsolidation

Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Fresenius Medical Care Net Profit Rises on Cost Savings

Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter

Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Capital Square Delivers 147.63% Total Return* to Investors in Medical Building DST

Performance Overview